Immediate Impact

1 from Science/Nature 54 standout
Sub-graph 1 of 23

Citing Papers

Glioblastoma Therapy: Past, Present and Future
2024 Standout
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
2024 Standout
4 intermediate papers

Works of Yi Cheng being referenced

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
2019
β-Defensin 2 is a responsive biomarker of IL-17A–driven skin pathology in patients with psoriasis
2016

Author Peers

Author Last Decade Papers Cites
Yi Cheng 31 380 119 256 236 34 1.4k
Di Lü 4 771 178 287 284 66 2.2k
Lingli Yang 3 310 90 143 263 53 1.3k
Wende R. Reenstra 3 268 135 109 634 34 1.5k
Laura Cristina Ceafalan 3 649 81 94 138 39 1.4k
Mingzi Zhang 6 330 82 130 87 97 1.3k
Stephan Schäfer 3 1208 66 203 174 50 2.2k
Sarthak Sinha 7 651 149 88 315 51 1.9k
Young Hyun Jung 5 750 262 94 212 58 1.6k
John Gaffney 1 944 156 312 139 35 1.9k
Yu Chen 8 561 84 88 281 62 1.4k

All Works

Loading papers...

Rankless by CCL
2026